CytomX Therapeutics Earnings Calls

Q1 2025 Beat
$0.270 (50.00%)
Release date May 12, 2025
EPS estimate $0.180
EPS actual $0.270
EPS Surprise 50.00%
Revenue estimate 4M
Revenue actual 50.917M
Revenue Surprise 1,172.93%
Q4 2024 Beat
$0.220 (195.65%)
Release date Mar 06, 2025
EPS estimate -$0.230
EPS actual $0.220
EPS Surprise 195.65%
Revenue estimate 13.04M
Revenue actual 38.093M
Revenue Surprise 192.12%
Q3 2024 Beat
$0.0700 (141.18%)
Release date Nov 07, 2024
EPS estimate -$0.170
EPS actual $0.0700
EPS Surprise 141.18%
Revenue estimate 13.533M
Revenue actual 33.432M
Revenue Surprise 147.03%
Q2 2024 Missed
-$0.0800 (-14.29%)
Release date Aug 08, 2024
EPS estimate -$0.0700
EPS actual -$0.0800
EPS Surprise -14.29%
Revenue estimate 19.99M
Revenue actual 25.115M
Revenue Surprise 25.64%

Last 4 Quarters for CytomX Therapeutics

Below you can see how CTMX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Missed
Release date Aug 08, 2024
Fiscal end date Jun 30, 2024
Price on release $1.18
EPS estimate -$0.0700
EPS actual -$0.0800
EPS surprise -14.29%
Date Price
Aug 02, 2024 $1.31
Aug 05, 2024 $1.26
Aug 06, 2024 $1.26
Aug 07, 2024 $1.16
Aug 08, 2024 $1.18
Aug 09, 2024 $1.20
Aug 12, 2024 $1.19
Aug 13, 2024 $1.16
Aug 14, 2024 $1.16
4 days before -9.92%
4 days after -1.69%
On release day 1.69%
Change in period -11.45%
Q3 2024 Beat
Release date Nov 07, 2024
Fiscal end date Sep 30, 2024
Price on release $1.00
EPS estimate -$0.170
EPS actual $0.0700
EPS surprise 141.18%
Date Price
Nov 01, 2024 $1.05
Nov 04, 2024 $1.01
Nov 05, 2024 $0.99
Nov 06, 2024 $1.00
Nov 07, 2024 $1.00
Nov 08, 2024 $1.09
Nov 11, 2024 $1.04
Nov 12, 2024 $1.04
Nov 13, 2024 $1.01
4 days before -4.76%
4 days after 1.00%
On release day 9.00%
Change in period -3.81%
Q4 2024 Beat
Release date Mar 06, 2025
Fiscal end date Dec 31, 2024
Price on release $0.617
EPS estimate -$0.230
EPS actual $0.220
EPS surprise 195.65%
Date Price
Feb 28, 2025 $0.677
Mar 03, 2025 $0.650
Mar 04, 2025 $0.653
Mar 05, 2025 $0.615
Mar 06, 2025 $0.617
Mar 07, 2025 $0.665
Mar 10, 2025 $0.670
Mar 11, 2025 $0.620
Mar 12, 2025 $0.599
4 days before -8.85%
4 days after -3.00%
On release day 7.71%
Change in period -11.58%
Q1 2025 Beat
Release date May 12, 2025
Fiscal end date Mar 31, 2025
Price on release $2.13
EPS estimate $0.180
EPS actual $0.270
EPS surprise 50.00%
Date Price
May 06, 2025 $0.97
May 07, 2025 $0.96
May 08, 2025 $1.09
May 09, 2025 $0.93
May 12, 2025 $2.13
May 13, 2025 $2.50
May 14, 2025 $2.38
May 15, 2025 $2.00
May 16, 2025 $2.03
4 days before 120.41%
4 days after -4.69%
On release day 17.37%
Change in period 110.06%

CytomX Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for CTMX?
CytomX Therapeutics (CTMX) has scheduled its earnings report for Aug 14, 2025 after the markets close.

What is the CTMX price-to-earnings (P/E) ratio?
CTMX P/E ratio as of May 16, 2025 (TTM) is 4.98.

What is the CTMX EPS forecast?
The forecasted EPS (Earnings Per Share) for CytomX Therapeutics (CTMX) for the first fiscal quarter 2025 is $0.0600.

What are CytomX Therapeutics's retained earnings?
On its balance sheet, CytomX Therapeutics reported retained earnings of $50.92 million for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CYTOMX THERAPEUTICS
CytomX Therapeutics
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...
GOLDEN STAR
Ticker Change Signal Date
IEP
$8.75
11.43% May 09
JLL
$229.63
2.75% May 09
UAA
$5.84
14.90% May 09
IIPR
$54.61
4.30% May 09
MEDP
$300.81
1.61% May 08

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE